Teva intros generic Axiron in the U.S.
JERUSALEM — Teva late last week announced the launch of generic Axiron (testosterone) topical solution CIII, 30-mg-1.5-mL, in the United States.
Testosterone topical solution CIII is a prescription medicine used to treat adult males who have low or no testosterone due to certain medical conditions. It is supplied in a metered dose pump with an underarm applicator.
Axiron had annual sales of approximately $247 million in the U.S., according to IMS data as of May 2017.
Upsher-Smith launches new website for Qudexy XR
MAPLE GROVE, Minn. — Upsher-Smith Laboratories on Monday announced the launch of its enhanced website for Qudexy XR (topiramate) extended-release capsules.
The site features Upsher-Smith’s Access Pathways Program designed to reduce the barriers associated with prescribing the medication and offers healthcare professionals the tools they need to help patients start Qudexy XR therapy, the company said. These tools include an informational video, a guide on how to get started and a patient enrollment form. In addition to being indicated to treat certain types of seizures, Qudexy XR is now indicated for use in the prevention of migraine headache in adults and adolescents 12 years of age or older.
“Upsher-Smith understands that access and affordability for extended-release brand products can be a challenge for patients and an administrative hurdle for physician offices,” said Rusty Field, president and CEO, Upsher-Smith. “The updated website offers resources that will allow them to prescribe Qudexy XR with greater ease.”
Eligible patients enrolled in the Access Pathways Program will receive a $0 co-pay offer. Patients paying cash or those who many not have insurance will benefit from a low-cost option, according to the company. The program also offers:
- Benefit verification
- Prior authorization support
- E-voucher pharmacy finder
- Pharmacy stocking assistance
Click here for more information on Qudexy XR.
NACDS, coalition ads thank legislators for backing pro-patient, pro-pharmacy bill
In newspaper ads placed in selected Congressional districts this August, NACDS is thanking members of the U.S. House of Representatives for co-sponsoring the Pharmacy and Medically Underserved Areas Enhancement Act (H.R. 592/S. 109). NACDS also is urging the members of Congress to work toward ultimate passage and enactment of the legislation.
The bill would allow people covered by Medicare to obtain basic healthcare services from their pharmacists. It would apply to those who are considered to have fewer healthcare access solutions than most, and to services that pharmacists are allowed to perform under state laws. Related services could include basic health tests, immunizations, tests for flu or strep throat and help with managing such chronic illnesses as diabetes. Medicare beneficiaries already can receive such services from nurse practitioners and physician assistants. NACDS emphasizes that pharmacists are highly qualified to provide many services beyond medication dispensing by virtue of the minimum six-year doctor of pharmacy degree that is required to sit for the pharmacy license exam.
In the ads, NACDS highlights the popularity of the concept behind the bill, based on opinion research conducted by Morning Consult and commissioned by NACDS. This research also was the basis for a new NACDS opinion research dashboard, which was released earlier this year. The research’s results can be reported at the state and Congressional district levels. Roughly 8-in-10 respondents support the ability of Medicare patients to obtain various healthcare services from pharmacists. Notably, support for this concept runs equally strong among those who voted for President Donald Trump, those who voted for Hillary Clinton and those who voted for another candidate in the 2016 presidential election.
NACDS’ print ads complement similar radio and digital ads by the Patient Access to Pharmacists’ Care Coalition, or PAPCC, which also are appearing in selected Congressional districts this August. NACDS is a Steering Committee member of PAPCC.